The U.S. Food and Drug Administration (FDA) has started a safety study of the medication mifepristone, which could lead to new restrictions on how the drug is distributed.

美國食品藥品醫療器材管理局 (FDA) 已開始對 Mifepristone 這種藥物進行安全性研究，這可能會導致藥物分發面臨新的限制。

The FDA is moving toward stricter oversight of mifepristone, a drug approved in 2000 for early pregnancy termination. This study will analyze hundreds of thousands of cases over six months, with early results expected in July. This initiative is caused by pressure from anti-abortion groups and a legal requirement from a Louisiana court. Although the FDA still states that the drug is safe on its official websites, the administration is using existing safety systems and may hire external experts to ensure the study is legally sound.

FDA 正趨向對 2000 年獲批用於早期終止妊娠的藥物 Mifepristone 實施更嚴格的監管。這項研究將在六個月內分析數十萬個案例，預計七月會得出初步結果。此舉是由於反墮胎團體的壓力以及路易斯安那州法院的法律要求所致。儘管 FDA 在官方網站上仍聲明該藥物是安全的，但行政部門正利用現有的安全系統，並可能聘請外部專家，以確保研究在法律上是健全的。

Different groups have very different views on this review. Anti-abortion advocates and some members of Congress emphasize that telehealth distribution has caused negative health outcomes; therefore, they want to return to requiring in-person visits. On the other hand, reproductive rights organizations assert that the review is a political move to limit access. They argue that the drug is safe, citing research and the fact that over 7.5 million patients have used it. Furthermore, the situation is complicated by the departure of former FDA Commissioner Marty Makary, who believed new data systems were needed for such a study.

不同團體對此次審查持有截然不同的看法。反墮胎倡導者和部分國會議員強調，遠端醫療分發導致了負面的健康結果；因此，他們希望恢復要求親自就診。另一方面，生殖權利組織則主張此次審查是限制獲取藥物的政治手段。他們引用研究以及超過 750 萬名患者使用過該藥的事實，認為該藥物是安全的。此外，前 FDA 局長 Marty Makary 的離職使情況更加複雜，他認為進行此類研究需要新的數據系統。

Legal and political events have also influenced these regulations. After Roe v. Wade was overturned and telehealth prescriptions increased, the 5th Circuit Court of Appeals briefly brought back in-person requirements. However, the Supreme Court later stopped this move to maintain current access during the legal battle. While the Trump administration generally supports state-level control over abortion policy, some allies are pushing for federal action to restrict the drug's availability via mail or telehealth.

法律和政治事件也影響了這些監管規定。在 Roe v. Wade 被推翻且遠端醫療處方增加後，第五巡迴上訴法院曾短暫恢復親自就診要求。然而，最高法院隨後阻止了這一舉動，以在法律爭議期間維持目前的獲取渠道。雖然川普政府通常支持州級控制墮胎政策，但部分盟友正推動聯邦採取行動，限制透過郵件或遠端醫療獲取該藥物。

The FDA is currently reviewing the safety of mifepristone, with results expected by the end of the year. These findings may change the future rules for how the drug is distributed.

FDA 目前正在審查 Mifepristone 的安全性，預計結果將於年底前公布。這些發現可能會改變未來關於藥物分發的規則。